In short
This article discusses the ongoing clinical trials of BGB-15025 Citrate, a promising drug being studied for the treatment of advanced non-small cell lung cancer (NSCLC). The trials aim to evaluate the effectiveness and safety of BGB-15025 Citrate in combination with other investigational agents and chemotherapy for patients with previously untreated, locally advanced, unresectable, or metastatic NSCLC.
At a glance
- Drug Name
- BGB-15025 Citrate
- Form
- Film-coated tablet
- Condition Studied
- Advanced Non-Small Cell Lung Cancer (NSCLC)
- Trial Phase
- Phase 2
- Main Objective
- Assess antitumor activity of tislelizumab plus investigational agents (including BGB-15025) with or without chemotherapy
- Key Eligibility Criteria
- Confirmed NSCLC, no prior systemic treatment for metastatic NSCLC, measurable lesions, good performance status
- Primary Endpoint
- Confirmed overall response rate (ORR)
- Secondary Endpoints
- Progression-free survival, duration of response, safety and tolerability, pharmacokinetics, immunogenicity
- Maximum Daily Dose
- 150 mg
- Maximum Treatment Period
- 24 months
What is BGB-15025 CITRATE?
BGB-15025 CITRATE is an investigational drug currently being studied for its potential in treating certain types of lung cancer. It is being developed by BeiGene, a pharmaceutical company focused on innovative cancer treatments. As an investigational drug, BGB-15025 CITRATE is still in the testing phase and is not yet approved for general use outside of clinical trials.
What condition does BGB-15025 CITRATE target?
BGB-15025 CITRATE is being studied for the treatment of Non-Small Cell Lung Cancer (NSCLC), specifically in patients with advanced stages of the disease. This includes: Locally advanced NSCLC: Cancer that has spread to nearby tissues or lymph nodes but has not spread to other parts of the body. Unresectable NSCLC: Cancer that cannot be removed completely through surgery. Metastatic NSCLC: Cancer that has spread from the lungs to other parts of the body. These are serious conditions that often require innovative treatment approaches.
Current Clinical Trial Information
BGB-15025 CITRATE is currently being studied in a Phase 2 clinical trial. This trial is part of a larger study called a "master protocol" which is investigating several potential treatments for NSCLC. The specific details of this trial are as follows: Trial Name: "A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer." Trial Phase: Phase 2 Trial Design: Open-label, multi-arm study Main Focus: To assess how well tislelizumab (another investigational drug) works in combination with other investigational agents (like BGB-15025 CITRATE) with or without chemotherapy.
How is BGB-15025 CITRATE administered?
According to the trial information, BGB-15025 CITRATE is administered as a film-coated tablet taken orally. The maximum daily dose being studied is 150 mg, with a total maximum dose of 113.4 g over a treatment period of up to 24 months. It's important to note that these dosages are specific to the clinical trial and may not represent the final recommended dosage if the drug is approved in the future.
Who is eligible for the clinical trial?
The clinical trial has specific criteria for who can participate. Some key eligibility factors include: Patients with confirmed NSCLC (nonsquamous or squamous) that is locally advanced, recurrent, or metastatic No prior systemic treatment for metastatic NSCLC Measurable tumor as defined by specific criteria (RECIST v1.1) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, which indicates the patient's ability to perform daily activities There are also several exclusion criteria, such as having mixed small cell lung cancer or certain genetic mutations. It's crucial to discuss with a healthcare provider to determine if one might be eligible for this or other clinical trials.
What are the objectives of the study?
The main goals of the study involving BGB-15025 CITRATE are: To assess how well the combination of tislelizumab and investigational agents (like BGB-15025 CITRATE) work against the cancer To evaluate the safety and tolerability of these drug combinations To understand how the drugs interact with the body (pharmacokinetics) To assess if the body develops an immune response to the drugs These objectives help researchers determine if BGB-15025 CITRATE, in combination with other treatments, could be an effective and safe option for patients with NSCLC.
Potential Benefits and Considerations
While BGB-15025 CITRATE shows promise, it's important to understand that as an investigational drug, its full benefits and risks are not yet known. Potential benefits could include: A new treatment option for advanced NSCLC Possibility of improved outcomes when combined with other treatments Contribution to the advancement of cancer research However, participants in clinical trials should also be aware of potential risks and considerations: Unknown side effects The treatment may not be effective for everyone Regular medical visits and tests are required It's crucial for patients to discuss all options, including clinical trials, with their healthcare team to make informed decisions about their treatment.